Skip to main content

Prolonged Use of Progestogens May Raise Risk for Intracranial Meningioma

Medically reviewed by Carmen Pope, BPharm. Last updated on March 29, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 29, 2024 -- Prolonged use of medrogestone, medroxyprogesterone acetate, and promegestone is associated with an increased risk for intracranial meningioma, according to a study published online March 27 in The BMJ.

Noémie Roland, M.D., M.P.H., from the EPI-PHARE Scientific Interest Group in Saint-Denis, France, and colleagues conducted a national case-control study involving 108,366 women overall to examine the risk for intracranial meningioma associated with use of selected progestogens. Cases included 18,061 women living in France who had intracranial surgery for meningioma between Jan. 1, 2009, and Dec. 31, 2018; each case was matched to five controls (90,305 controls).

The researchers found that the risk for meningioma was increased with use of medrogestone (0.2 percent among cases versus 0.1 percent among controls; odds ratio, 3.49), medroxyprogesterone acetate (injectable; 0.05 versus 0.01 percent; odds ratio 5.55), and promegestone (0.5 versus 0.2 percent; odds ratio, 2.39). The excess risk was driven by use for one year or longer. No excess risk for intracranial meningioma was seen for progesterone, dydrogesterone, or levonorgestrel intrauterine systems. Due to the small number of people receiving dienogest or hydroxyprogesterone, no conclusions could be drawn.

"Future studies should further clarify the association between the duration of use and risk for the progestogens studied, and extend the discussion of meningioma risk to dienogest and hydroxyprogesterone," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Read this next

Brain Cancer Risk Increased After Moderate/Severe, Penetrating TBI

FRIDAY, Feb. 16. 2024 -- Moderate/severe and penetrating traumatic brain injury (TBI) are associated with an increased risk for subsequent development of brain cancer, according...

Preop Stereotactic Radiosurgery May Aid Outcomes With Resected Brain Metastases

MONDAY, July 10, 2023 -- Preoperative stereotactic radiosurgery (SRS) may be effective for patients with resected brain metastases, according to a study published online June 8 in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.